{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T22:44:43Z","timestamp":1759963483513,"version":"3.37.3"},"reference-count":30,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,2,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Antibody-drug conjugates (ADCs) are a new class of therapeutics that use antibodies to deliver potent cytotoxic drugs selectively to cancer cells. CD203c, an ecto-nucleotide pyrophosphatase-phosphodiesterase 3, is overexpressed on neoplastic mast cells (MCs) in systemic mastocytosis (SM), thus representing a promising target for antibody-mediated therapy. In this study, we have found that human neoplastic MC lines (ROSAKIT\u2009D816V and ROSAKIT\u2009D816V-Gluc), which express high levels of CD203c, are highly and specifically sensitive to the antiproliferative effects of an ADC against CD203c (AGS-16C3F). In these cell lines, AGS-16C3F induced cell apoptosis at very low concentrations. To characterize the effects of AGS-16C3F on leukemia progression in vivo, ROSAKIT\u2009D816V-Gluc NOD-SCID \u03b3 mouse models of advanced SM (AdvSM) were treated with AGS-16C3F or an ADC control for 2 weeks. Whereas AGS-16C3F had no apparent toxicity in xenotransplanted mice, in vivo neoplastic MC burden significantly decreased in both hematopoietic and nonhematopoietic organs. Furthermore, animals treated with AGS-16C3F had prolonged survival compared with the animals treated with control ADC, and AGS-16C3F efficiently prevented disease relapse. In conclusion, these preclinical studies identified CD203c as a novel therapeutic target on neoplastic MCs, and AGS-16C3F as a promising ADC for the treatment of patients with AdvSM.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018026179","type":"journal-article","created":{"date-parts":[[2019,2,25]],"date-time":"2019-02-25T17:09:22Z","timestamp":1551114562000},"page":"633-643","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["In vitro and in vivo efficacy of an anti-CD203c conjugated antibody (AGS-16C3F) in mouse models of advanced systemic mastocytosis"],"prefix":"10.1182","volume":"3","author":[{"given":"Yanyan","family":"Zhang","sequence":"first","affiliation":[{"name":"INSERM, Unit\u00e9 Mixte de Recherche (UMR) 1170, Villejuif, France;"},{"name":"Universit\u00e9 Paris-Saclay, Gustave Roussy, Villejuif, France;"},{"name":"Gustave Roussy, Villejuif, France;"},{"name":"INSERM U942, H\u00f4pital Lariboisi\u00e8re, Paris, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghaith","family":"Wedeh","sequence":"additional","affiliation":[{"name":"Laboratoire de Biologie et Pharmacologie Appliqu\u00e9e, Centre National de la Recherche Scientifique (CNRS) UMR8113, Ecole Normale Sup\u00e9rieure de Cachan, Cachan, France;"},{"name":"Faculty of Pharmacy, Tishreen University, Latakia, Syria;"},{"name":"INSERM U942, H\u00f4pital Lariboisi\u00e8re, Paris, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"He","sequence":"additional","affiliation":[{"name":"INSERM, Unit\u00e9 Mixte de Recherche (UMR) 1170, Villejuif, France;"},{"name":"Universit\u00e9 Paris-Saclay, Gustave Roussy, Villejuif, France;"},{"name":"Gustave Roussy, Villejuif, France;"},{"name":"INSERM U942, H\u00f4pital Lariboisi\u00e8re, Paris, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8029-8473","authenticated-orcid":false,"given":"Monika","family":"Wittner","sequence":"additional","affiliation":[{"name":"INSERM, Unit\u00e9 Mixte de Recherche (UMR) 1170, Villejuif, France;"},{"name":"Universit\u00e9 Paris-Saclay, Gustave Roussy, Villejuif, France;"},{"name":"Gustave Roussy, Villejuif, France;"},{"name":"INSERM U942, H\u00f4pital Lariboisi\u00e8re, Paris, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Beghi","sequence":"additional","affiliation":[{"name":"INSERM, Unit\u00e9 Mixte de Recherche (UMR) 1170, Villejuif, France;"},{"name":"Universit\u00e9 Paris-Saclay, Gustave Roussy, Villejuif, France;"},{"name":"Gustave Roussy, Villejuif, France;"},{"name":"INSERM U942, H\u00f4pital Lariboisi\u00e8re, Paris, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviane","family":"Baral","sequence":"additional","affiliation":[{"name":"INSERM, Unit\u00e9 Mixte de Recherche (UMR) 1170, Villejuif, France;"},{"name":"Universit\u00e9 Paris-Saclay, Gustave Roussy, Villejuif, France;"},{"name":"Gustave Roussy, Villejuif, France;"},{"name":"INSERM U942, H\u00f4pital Lariboisi\u00e8re, Paris, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2331-4024","authenticated-orcid":false,"given":"Jean-Marie","family":"Launay","sequence":"additional","affiliation":[{"name":"Agensys, Inc., Santa Monica, CA;"},{"name":"INSERM U942, H\u00f4pital Lariboisi\u00e8re, Paris, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4664-5686","authenticated-orcid":false,"given":"Siham","family":"Bibi","sequence":"additional","affiliation":[{"name":"Laboratoire de Biologie et Pharmacologie Appliqu\u00e9e, Centre National de la Recherche Scientifique (CNRS) UMR8113, Ecole Normale Sup\u00e9rieure de Cachan, Cachan, France;"},{"name":"INSERM U942, H\u00f4pital Lariboisi\u00e8re, Paris, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Do\u00f1ate","sequence":"additional","affiliation":[{"name":"Fulcrum 2020, Los Angeles, CA;"},{"name":"INSERM U942, H\u00f4pital Lariboisi\u00e8re, Paris, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hosein","family":"Kouros-Mehr","sequence":"additional","affiliation":[{"name":"Laboratory of Hematology, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France; and"},{"name":"INSERM U942, H\u00f4pital Lariboisi\u00e8re, Paris, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6714-7478","authenticated-orcid":false,"given":"Michel","family":"Arock","sequence":"additional","affiliation":[{"name":"Laboratoire de Biologie et Pharmacologie Appliqu\u00e9e, Centre National de la Recherche Scientifique (CNRS) UMR8113, Ecole Normale Sup\u00e9rieure de Cachan, Cachan, France;"},{"name":"CNRS Groupement de Recherche 3697 MicroNiT, Villejuif, France"},{"name":"INSERM U942, H\u00f4pital Lariboisi\u00e8re, Paris, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4247-5421","authenticated-orcid":false,"given":"Fawzia","family":"Louache","sequence":"additional","affiliation":[{"name":"INSERM, Unit\u00e9 Mixte de Recherche (UMR) 1170, Villejuif, France;"},{"name":"Universit\u00e9 Paris-Saclay, Gustave Roussy, Villejuif, France;"},{"name":"Gustave Roussy, Villejuif, France;"},{"name":"CNRS Groupement de Recherche 3697 MicroNiT, Villejuif, France"},{"name":"INSERM U942, H\u00f4pital Lariboisi\u00e8re, Paris, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2019,2,25]]},"reference":[{"issue":"10","key":"2020021108331415200_B1","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3324\/haematol.2016.146563","article-title":"Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice","volume":"101","author":"Ustun","year":"2016","journal-title":"Haematologica"},{"issue":"10","key":"2020021108331415200_B2","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/all.12436","article-title":"Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis","volume":"69","author":"Valent","year":"2014","journal-title":"Allergy"},{"issue":"6","key":"2020021108331415200_B3","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-16-2234","article-title":"Advances in the classification and treatment of mastocytosis: current status and outlook toward the future","volume":"77","author":"Valent","year":"2017","journal-title":"Cancer Res"},{"issue":"6","key":"2020021108331415200_B4","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/ejh.12544","article-title":"Current treatment options in patients with mastocytosis: status in 2015 and future perspectives","volume":"94","author":"Arock","year":"2015","journal-title":"Eur J Haematol"},{"issue":"11","key":"2020021108331415200_B5","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1002\/ajh.24553","article-title":"Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management","volume":"91","author":"Pardanani","year":"2016","journal-title":"Am J Hematol"},{"issue":"1","key":"2020021108331415200_B6","first-page":"111","article-title":"Smouldering systemic mastocytosis: a rare disorder with a difficult diagnosis","volume":"61","author":"Shah","year":"2011","journal-title":"J Pak Med Assoc"},{"issue":"6","key":"2020021108331415200_B7","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"2020021108331415200_B8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2141.2007.06619.x","article-title":"Recent advances in the understanding of mastocytosis: the role of KIT mutations","volume":"138","author":"Orfao","year":"2007","journal-title":"Br J Haematol"},{"issue":"10","key":"2020021108331415200_B9","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1093\/annonc\/mdx290","article-title":"Midostaurin: a magic bullet that blocks mast cell expansion and activation","volume":"28","author":"Valent","year":"2017","journal-title":"Ann Oncol"},{"issue":"6","key":"2020021108331415200_B10","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","article-title":"Antibody-drug conjugates for cancer therapy","volume":"17","author":"Thomas","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"2020021108331415200_B11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4161\/mabs.27436","article-title":"Antibody-drug conjugates: present and future","volume":"6","author":"Beck","year":"2014","journal-title":"MAbs"},{"issue":"5","key":"2020021108331415200_B12","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.biologicals.2015.05.006","article-title":"Antibody-drug conjugates for cancer therapy: The technological and regulatory challenges of developing drug-biologic hybrids","volume":"43","author":"Hamilton","year":"2015","journal-title":"Biologicals"},{"issue":"2","key":"2020021108331415200_B13","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/bcp.12044","article-title":"Drug-conjugated antibodies for the treatment of cancer","volume":"76","author":"Lambert","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"2020021108331415200_B14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1146\/annurev-med-050311-201823","article-title":"Antibody-drug conjugates in cancer therapy","volume":"64","author":"Sievers","year":"2013","journal-title":"Annu Rev Med"},{"issue":"7","key":"2020021108331415200_B15","first-page":"2343","article-title":"The monoclonal antibody 97A6 defines a novel surface antigen expressed on human basophils and their multipotent and unipotent progenitors","volume":"94","author":"B\u00fchring","year":"1999","journal-title":"Blood"},{"issue":"5","key":"2020021108331415200_B16","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00281-016-0564-2","article-title":"Regulation of allergic inflammation by the ectoenzyme E-NPP3 (CD203c) on basophils and mast cells","volume":"38","author":"Tsai","year":"2016","journal-title":"Semin Immunopathol"},{"issue":"8","key":"2020021108331415200_B17","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1158\/1078-0432.CCR-15-1542","article-title":"AGS16F is a novel antibody drug conjugate directed against ENPP3 for the treatment of renal cell carcinoma","volume":"22","author":"Do\u00f1ate","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2020021108331415200_B18","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/10428190601072293","article-title":"CD203c \/CD117-, an useful phenotype profile for acute basophilic leukaemia diagnosis in cases of undifferentiated blasts","volume":"48","author":"Staal-Viliare","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2020021108331415200_B19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.canlet.2003.11.002","article-title":"Expression and localization of ecto-nucleotide pyrophosphatase\/phosphodiesterase I-1 (E-NPP1\/PC-1) and -3 (E-NPP3\/CD203c\/PD-Ibeta\/B10\/gp130(RB13-6)) in inflammatory and neoplastic bile duct diseases","volume":"207","author":"Yano","year":"2004","journal-title":"Cancer Lett"},{"issue":"5","key":"2020021108331415200_B20","first-page":"763","article-title":"Expression and localization of ecto-nucleotide pyrophosphatase\/phosphodiesterase I-3 (E-NPP3\/CD203c\/PD-I beta\/B10\/gp130RB13-6) in human colon carcinoma","volume":"12","author":"Yano","year":"2003","journal-title":"Int J Mol Med"},{"issue":"2","key":"2020021108331415200_B21","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.immuni.2015.01.015","article-title":"The ectoenzyme E-NPP3 negatively regulates ATP-dependent chronic allergic responses by basophils and mast cells","volume":"42","author":"Tsai","year":"2015","journal-title":"Immunity"},{"issue":"4","key":"2020021108331415200_B22","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1177\/039463200802100404","article-title":"CD203c is overexpressed on neoplastic mast cells in systemic mastocytosis and is upregulated upon IgE receptor cross-linking","volume":"21","author":"Hauswirth","year":"2008","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"Suppl 15","key":"2020021108331415200_B23","article-title":"Phase I studies of anti-ENPP3 antibody drug conjugates (ADCs) in advanced refractory renal cell carcinomas (RRCC) [abstract]","volume":"33","author":"Thompson","year":"2015","journal-title":"J Clin Oncol"},{"issue":"50","key":"2020021108331415200_B24","doi-asserted-by":"crossref","first-page":"82985","DOI":"10.18632\/oncotarget.12824","article-title":"A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase","volume":"7","author":"Bibi","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"2020021108331415200_B25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/blood-2013-10-534685","article-title":"A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection","volume":"124","author":"Saleh","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2020021108331415200_B26","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-3083.1994.tb03404.x","article-title":"Phenotypic characterization of the human mast-cell line HMC-1","volume":"39","author":"Nilsson","year":"1994","journal-title":"Scand J Immunol"},{"issue":"11","key":"2020021108331415200_B27","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1038\/leu.2015.138","article-title":"Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia","volume":"29","author":"Wedeh","year":"2015","journal-title":"Leukemia"},{"issue":"4","key":"2020021108331415200_B28","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/mt.2012.38","article-title":"A water-soluble coelenterazine for sensitive in vivo imaging of coelenterate luciferases","volume":"20","author":"Morse","year":"2012","journal-title":"Mol Ther"},{"issue":"10","key":"2020021108331415200_B29","doi-asserted-by":"crossref","first-page":"e396","DOI":"10.1038\/cddis.2012.137","article-title":"CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model","volume":"3","author":"Zhang","year":"2012","journal-title":"Cell Death Dis"},{"issue":"2","key":"2020021108331415200_B30","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10549-010-1090-x","article-title":"Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer","volume":"128","author":"Junttila","year":"2011","journal-title":"Breast Cancer Res Treat"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/4\/633\/1631309\/advances026179.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/4\/633\/1631309\/advances026179.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T09:00:57Z","timestamp":1581411657000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/4\/633\/246778\/In-vitro-and-in-vivo-efficacy-of-an-antiCD203c"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,25]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,2,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018026179","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"subject":[],"published":{"date-parts":[[2019,2,25]]}}}